EBV‐specific cytotoxic T lymphocytes for refractory EBV‐associated post‐transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review

Transplant InternationalVolume 34, Issue 12 p. 2483-2493 Review Article EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review Jing-Yi Liu, Jing-Yi Liu Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China Clinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing, China National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China These authors contributed equally to this work.Search for more papers by this authorJin-Ming Zhang, Jin-Ming Zhang Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China Clinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing, China National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China These authors contributed equally to this work.Search for more papers by this authorHao-Su Zhan, Hao-Su Zhan Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China Clinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing, China National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this authorLi-Ying Sun, Corresponding Author Li-Ying Sun sunxlx@outlook.com Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China Clinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing, China National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China Intensive Care Unit, Beijing Friendship Hospital, Capital Medical University, Beijing, China Correspondence Li-Ying Sun and Lin Wei, Liver transplantation center & Intensive Care Unit, Beijing Friendship Hospital,Capital Medical University. No.101 Luyuandong Road, Tongzhou District, Beijing 101100. Tel.: +86 18612596060 (L.-Y. S.); +86 18610932626 (L. W.); fax: +86-10-80838168; e-mails: sunxlx@outlook.com (L.-Y. S.); weilin@ccmu.edu.cn (L. W.)Search for more papers by this authorLin Wei, Corresponding Author Lin Wei weilin@ccmu.edu.cn Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China Clinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing, China National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China Correspondence Li-Ying Sun and Lin Wei, Liver transplantation center & Intensive Care Unit, Beijing Friendship Hospital,Capital Medical University. No.101 Luyuandong Road, Tongzhou District, Beijing 101100. Tel.: +86 18612596060 (L.-Y. S.); +86 18610932626 (L. W.); fax: +86-10-80838168; e-mails: sunxlx@outlook.com (L.-Y. S.); weilin@ccmu.edu.cn (L. W.)Search for more papers by this author Jing-Yi Liu, Jing-Yi Liu Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China Clinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing, China National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China These authors contributed equally to this work.Search for more papers by this authorJin-Ming Zhang, Jin-Ming Zhang Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China Clinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing, China National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China These authors contributed equally to this work.Search for more papers by this authorHao-Su Zhan, Hao-Su Zhan Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China Clinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing, China National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this authorLi-Ying Sun, Corresponding Author Li-Ying Sun sunxlx@outlook.com Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China Clinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing, China National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China Intensive Care Unit, Beijing Friendship Hospital, Capital Medical University, Beijing, China Correspondence Li-Ying Sun and Lin Wei, Liver transplantation center & Intensive Care Unit, Beijing Friendship Hospital,Capital Medical University. No.101 Luyuandong Road, Tongzhou District, Beijing 101100. Tel.: +86 18612596060 (L.-Y. S.); +86 18610932626 (L. W.); fax: +86-10-80838168; e-mails: sunxlx@outlook.com (L.-Y. S.); weilin@ccmu.edu.cn (L. W.)Search for more papers by this authorLin Wei, Corresponding Author Lin Wei weilin@ccmu.edu.cn Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China Clinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing, China National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China Correspondence Li-Ying Sun and Lin Wei, Liver transplantation center & Intensive Care Unit, Beijing Friendship Hospital,Capital Medical University. No.101 Luyuandong Road, Tongzhou District, Beijing 101100. Tel.: +86 18612596060 (L.-Y. S.); +86 18610932626 (L. W.); fax: +86-10-80838168; e-mails: sunxlx@outlook.com (L.-Y. S.); weilin@ccmu.edu.cn (L. W.)Search for more papers by this author First published: 12 September 2021 https://doi.org/10.1111/tri.14107 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Summary The use of Epstein–Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) in adoptive immunotherapy in hematopoietic stem cell transplantation (HSCT) patients with post-transplantation lymphoproliferative disorder (PTLD) has demonstrated safety and effectiveness. EBV-CTLs might also be the effective treatment of refractory PTLD of solid organ transplantation (SOT) recipients. Two independent assessors searched Pubmed, Embase, Cochrane Library, and Web of Science from their inception to November 2020. Eleven studies with 76 patients (42, 55% male) were included. We extracted the data and completed the quality assessments. Most of the studies were from Europe and the USA. Liver and kidney transplantation accounted for most of the transplant types. Thirty-five (46.1%) patients were diagnosed with monomorphic PTLD, and B lymphocyte type was the most common. All the patients received primary treatment for PTLD while it was ineffective. CTLs included autologous EBV-CTLs (15/76, 22%) and HLA-matched third-party EBV-CTLs (61/76, 78%). The response rate for EBV-CTL treatment of refractory PTLD was 66%. Of 50 patients, 36 achieved complete remission and 14 achieved partial remission. EBV-DNA level decreased in 39 patients. Adverse reactions were rare and mild. We conclude that adoptive therapy with EBV-specific CTLs is safe, well-tolerated, and effective in PTLD. Volume34, Issue12December 2021Pages 2483-2493 RelatedInformation